Rang	Name	Position
1	Mr. Thomas Lingelbach	President, CEO & Director
2	Mr. Peter Buhler	Chief Financial Officer
3	Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer
4	Ms. Dipal Patel	Chief Commercial Officer
5	Mr. Vincent Dequenne	Chief Operating Officer
6	Dr. Hanneke Schuitemaker Ph.D.	Chief Scientific Officer
7	Mr. Joshua Drumm Ph.D.	Vice President of Investor Relations
8	Ms. Kendra Wergin	General Counsel & Corporate Secretary
9	Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations
10	Ms. Petra Pesendorfer	Chief People Officer

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	Frazier Life Sciences Management, L.P.	2,42%	15,26 Mio. USD
2	Novo A/S	1,12%	7,04 Mio. USD
3	Vivo Capital, LLC	0,80%	5,08 Mio. USD
4	General American Investors Co Inc	0,37%	2,36 Mio. USD
5	Millennium Management LLC	0,14%	0,90 Mio. USD
6	Wells Fargo & Co	0,08%	0,52 Mio. USD
7	Morgan Stanley - Brokerage Accounts	0,05%	0,31 Mio. USD
8	Ironwood Investment Management LLC	0,03%	0,17 Mio. USD
9	HRT FINANCIAL LLC	0,02%	0,14 Mio. USD
10	Citadel Advisors Llc	0,02%	0,14 Mio. USD
11	OLD MISSION CAPITAL LLC.	0,01%	0,09 Mio. USD
12	VSM Wealth Advisory, LLC	0,01%	0,07 Mio. USD
13	GAMMA Investing LLC	0,00%	0,03 Mio. USD
14	Rhumbline Advisers	0,00%	0,01 Mio. USD
15	Steigerwald, Gordon & Koch Inc.	0,00%	0,01 Mio. USD
16	UBS Group AG	0,00%	0,01 Mio. USD
17	BNP Paribas Arbitrage, SA	0,00%	0,00 Mio. USD
18	Advisor Group Holdings, Inc.	0,00%	0,00 Mio. USD
19	Hartland & Co	0,00%	0,00 Mio. USD
20	Hanson Mcclain Inc	0,00%	0,00 Mio. USD